Are you Dr. Dugel?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 61 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1101 E Missouri Ave
Phoenix, AZ 85014Phone+1 602-222-2221Fax+1 602-266-2044
Summary
- Dr. Pravin Dugel, MD is a board certified ophthalmologist in Phoenix, Arizona. He is currently licensed to practice medicine in Arizona and California. He is affiliated with St. Joseph's Hospital and Medical Center, HonorHealth Scottsdale Osborn Medical Center, and HonorHealth Deer Valley Medical Center.
Education & Training
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Ophthalmology, 1988 - 1994
David Geffen School of Medicine at UCLAClass of 1988
Certifications & Licensure
AZ State Medical License 1994 - 2026
CA State Medical License 1990 - 2025- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Fellow (FAAO) American Academy of Ophthalmology
Clinical Trials
- Safety and Tolerability of MS-R001 in Patients With Diabetic Macular Edema Secondary to Diabetic Retinopathy Start of enrollment: 2006 Sep 01
- A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration Start of enrollment: 2007 Apr 01
- Safety and Tolerability Study of the Helical Intravitreal Triamcinolone Implant in Diabetic Macular Edema Start of enrollment: 2005 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 88 citationsEmixustat Hydrochloride for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Clinical TrialPhilip J. Rosenfeld, Pravin U. Dugel, Frank G. Holz, Jeffrey S. Heier, Joel A. Pearlman
Ophthalmology. 2018-04-28 - 44 citationsPhase ii, randomized, placebo-controlled, 90-day study of emixustat hydrochloride in geographic atrophy associated with dry age-related macular degeneration.Pravin U. Dugel, Roger L. Novack, Karl G. Csaky, Preston P. Richmond, David G. Birch
Retina. 2015-06-01 - 391 citationsTwo-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyQuan Dong Nguyen, Syed Mahmood Shah, Afsheen Khwaja, Roomasa Channa, Elham Hatef
Ophthalmology. 2010-11-01
Authored Content
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular DegenerationJuly 2020
- Join now to see all
Press Mentions
IVERIC Bio, Inc. (NASDAQ:ISEE) Q4 2022 Earnings Call TranscriptMarch 3rd, 2023- IVERIC Bio, Inc. (ISEE) Q1 2022 Earnings Call TranscriptMay 4th, 2022
- Iveric Bio Completes Patient Enrollment of GATHER2 Pivotal Clinical Trial of Zimura® Ahead of ScheduleJuly 26th, 2021
- Join now to see all
Professional Memberships
- Fellow
